Design and synthesis of new spirooxindole candidates and their selenium nanoparticles as potential dual Topo I/II inhibitors, DNA intercalators, and apoptotic inducers
暂无分享,去创建一个
A. El-Sayed | M. M. Khalifa | A. Elkamhawy | S. El-Kalyoubi | Kyeong Lee | Mahmoud T. Abo-Elfadl | A. Al-karmalawy
[1] A. Mourad,et al. Novel topoisomerase II/EGFR dual inhibitors: design, synthesis and docking studies of naphtho[2′,3′:4,5]thiazolo[3,2-a]pyrimidine hybrids as potential anticancer agents with apoptosis inducing activity , 2023, Journal of enzyme inhibition and medicinal chemistry.
[2] Ali Khalil Ali,et al. Novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as potential antitumor candidates targeting both EGFR and VEGFR-2; design, synthesis, biological evaluations, and in silico studies , 2023, RSC advances.
[3] M. Ghorab,et al. Synthesis, DFT calculations, and anti-proliferative evaluation of pyrimidine and selenadiazolopyrimidine derivatives as dual Topoisomerase II and HSP90 inhibitors , 2023, Journal of enzyme inhibition and medicinal chemistry.
[4] Hany E. A. Ahmed,et al. A novel class of phenylpyrazolone-sulphonamides rigid synthetic anticancer molecules selectively inhibit the isoform IX of carbonic anhydrases guided by molecular docking and orbital analyses , 2023, Journal of biomolecular structure & dynamics.
[5] A. Al-Taweel,et al. Cholinesterase Inhibitors from an Endophytic Fungus Aspergillus niveus Fv-er401: Metabolomics, Isolation and Molecular Docking , 2023, Molecules.
[6] X. Qiao,et al. Design, synthesis and biological evaluation of dual Topo II/HDAC inhibitors bearing pyrimido[5,4-b]indole and pyrazolo[3,4-d]pyrimidine motifs. , 2023, European journal of medicinal chemistry.
[7] C. Supuran,et al. 4-(5-Amino-pyrazol-1-yl)benzenesulfonamide derivatives as novel multi-target anti-inflammatory agents endowed with inhibitory activity against COX-2, 5-LOX and carbonic anhydrase: Design, synthesis, and biological assessments. , 2023, European journal of medicinal chemistry.
[8] Faten Farouk,et al. Investigating the potential anticancer activities of antibiotics as topoisomerase II inhibitors and DNA intercalators: in vitro, molecular docking, molecular dynamics, and SAR studies , 2023, Journal of enzyme inhibition and medicinal chemistry.
[9] S. Antar,et al. Ligand-Based Design on the Dog-Bone-Shaped BIBR1532 Pharmacophoric Features and Synthesis of Novel Analogues as Promising Telomerase Inhibitors with In Vitro and In Vivo Evaluations. , 2022, Journal of medicinal chemistry.
[10] A. Belal,et al. Screening a Panel of Topical Ophthalmic Medications against MMP-2 and MMP-9 to Investigate Their Potential in Keratoconus Management , 2022, Molecules.
[11] S. Sushanth Kumar,et al. Exploration of the Detailed Structure–Activity Relationships of Isatin and Their Isomers As Monoamine Oxidase Inhibitors , 2022, ACS omega.
[12] Ehab S. Taher,et al. Uracil as a Zn-Binding Bioisostere of the Allergic Benzenesulfonamide in the Design of Quinoline–Uracil Hybrids as Anticancer Carbonic Anhydrase Inhibitors , 2022, Pharmaceuticals.
[13] Kashif Haider,et al. A comprehensive review on pyrazoline based heterocyclic hybrids as potent anticancer agents , 2022, European Journal of Medicinal Chemistry Reports.
[14] Liao Dong,et al. Nickel supported on magnetic biochar as a highly efficient and recyclable heterogeneous catalyst for the one‐pot synthesis of spirooxindole‐dihydropyridines , 2022, Applied Organometallic Chemistry.
[15] F. Agili,et al. Synthesis, Molecular Docking and Anticancer Activity of Some 5‐Aryl‐5,10‐dihydropyrido[2,3‐ d :6,5‐ d′ ]dipyrimidine‐2,4,6,8‐tetraone Derivatives and Pyrido[2,3‐ d ]pyrimidines , 2022, ChemistrySelect.
[16] Mohamed S. Nafie,et al. Topo II inhibition and DNA intercalation by new phthalazine-based derivatives as potent anticancer agents: design, synthesis, anti-proliferative, docking, and in vivo studies , 2021, Journal of enzyme inhibition and medicinal chemistry.
[17] F. Agili,et al. Novel Uracil Derivatives Depicted Potential Anticancer Agents: In Vitro, Molecular Docking, and ADME Study , 2021, Arabian Journal of Chemistry.
[18] I. Shurygina,et al. Selenium Nanoparticles , 2021, Nanotechnology in Medicine.
[19] A. El-Sayed,et al. Synthesis, In Silico Prediction and In Vitro Evaluation of Antimicrobial Activity, DFT Calculation and Theoretical Investigation of Novel Xanthines and Uracil Containing Imidazolone Derivatives , 2021, International journal of molecular sciences.
[20] Chao Ma,et al. Design and Synthesis of New Quinoxaline Derivatives as Potential Histone Deacetylase Inhibitors Targeting Hepatocellular Carcinoma: In Silico, In Vitro, and SAR Studies , 2021, Frontiers in Chemistry.
[21] Shailee V. Tiwari,et al. Design and synthesis of novel conformationally constrained 7,12-dihydrodibenzo[b,h][1,6] naphthyridine and 7H-Chromeno[3,2-c] quinoline derivatives as topoisomerase I inhibitors: In vitro screening, molecular docking and ADME predictions. , 2021, Bioorganic chemistry.
[22] H. Santos,et al. Selenium Nanoparticles for Biomedical Applications: From Development and Characterization to Therapeutics , 2021, Advanced healthcare materials.
[23] M. Tajbakhsh,et al. Synthesis, in silico, in vitro and in vivo evaluations of isatin aroylhydrazones as highly potent anticonvulsant agents. , 2021, Bioorganic chemistry.
[24] Girinath G. Pillai,et al. In-silico driven design and development of spirobenzimidazo-quinazolines as potential DNA gyrase inhibitors. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[25] M. Elsohly,et al. Design, synthesis, and anti-proliferative evaluation of new quinazolin-4(3H)-ones as potential VEGFR-2 inhibitors. , 2020, Bioorganic & medicinal chemistry.
[26] F. Agili,et al. Synthesis, In Silico Prediction and In Vitro Evaluation of Antitumor Activities of Novel Pyrido[2,3-d]pyrimidine, Xanthine and Lumazine Derivatives , 2020, Molecules.
[27] M. Elsohly,et al. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation. , 2020, Bioorganic chemistry.
[28] M. Elsohly,et al. Design, synthesis, molecular modeling, in vivo studies and anticancer activity evaluation of new phthalazine derivatives as potential DNA intercalators and topoisomerase II inhibitors. , 2020, Bioorganic chemistry.
[29] Asmaa M. AboulMagd,et al. New fused pyrimidine derivatives with anticancer activity: Synthesis, topoisomerase II inhibition, apoptotic inducing activity and molecular modeling study. , 2020, Bioorganic chemistry.
[30] R. Baharfar,et al. Design and characterization of Fe 3 O 4 /GO/Au‐Ag nanocomposite as an efficient catalyst for the green synthesis of spirooxindole‐dihydropyridines , 2020 .
[31] T. Daveedu,et al. One-pot synthesis of thiazolo[3,2-a]pyrimidine derivatives, their cytotoxic evaluation and molecular docking studies. , 2020, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
[32] L. Legnani,et al. Pyridine and Pyrimidine Derivatives as Privileged Scaffolds in Biologically Active Agents. , 2020, Current medicinal chemistry.
[33] S. El-Metwally,et al. Design, molecular modeling and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as inhibitors of topoisomerase II. , 2019, Bioorganic chemistry.
[34] L. Armstrong,et al. Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations , 2019, Molecular Pharmacology.
[35] Varun,et al. Isatin and its derivatives: a survey of recent syntheses, reactions, and applications. , 2019, MedChemComm.
[36] L. Rashed,et al. Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in vitro biological evaluation, and QSAR studies , 2018, Journal of enzyme inhibition and medicinal chemistry.
[37] Herman Yeger,et al. Combination therapy in combating cancer , 2017, Oncotarget.
[38] Shuguang Yuan,et al. Using PyMOL as a platform for computational drug design , 2017 .
[39] A. Khalil,et al. Novel nanofibrillated cellulose/polyvinylpyrrolidone/silver nanoparticles films with electrical conductivity properties. , 2017, Carbohydrate polymers.
[40] K. Kohli,et al. Green Synthesis of Selenium Nanoparticles from Broccoli, Characterization, Application and Toxicity , 2017 .
[41] Anil H. Gore,et al. Synthesis, biological evaluation and molecular docking studies of some novel indenospiro derivatives as anticancer agents , 2016 .
[42] J. Ilaš,et al. Discovery of Benzothiazole Scaffold-Based DNA Gyrase B Inhibitors. , 2016, Journal of medicinal chemistry.
[43] Wenfeng Liu,et al. Discovery of 7‐Methyl‐10‐Hydroxyhomocamptothecins with 1,2,3‐Triazole Moiety as Potent Topoisomerase I Inhibitors , 2016, Chemical biology & drug design.
[44] N. Osheroff,et al. Effects of Olive Metabolites on DNA Cleavage Mediated by Human Type II Topoisomerases , 2015, Biochemistry.
[45] Ding Li,et al. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors. , 2015, European journal of medicinal chemistry.
[46] S. K. Mehta,et al. Surface functionalized selenium nanoparticles for biomedical applications. , 2014, Journal of biomedical nanotechnology.
[47] R. Nussinov,et al. The structural basis for cancer treatment decisions , 2014, Oncotarget.
[48] J. Bajorath,et al. Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.
[49] H. Watari,et al. Apoptosis and Molecular Targeting Therapy in Cancer , 2014, BioMed research international.
[50] M. Rosini,et al. Polypharmacology: the rise of multitarget drugs over combination therapies. , 2014, Future medicinal chemistry.
[51] L. Glavaš-Obrovac,et al. Antineoplastic DNA-Binding Compounds: Intercalating and Minor Groove Binding Drugs , 2013, Arhiv za higijenu rada i toksikologiju.
[52] Raj Kumar,et al. Synthesis of imine-pyrazolopyrimidinones and their mechanistic interventions on anticancer activity. , 2013, Bioorganic & medicinal chemistry.
[53] L. Ouyang,et al. Synthesis of novel spirooxindolo-pyrrolidines, pyrrolizidines, and pyrrolothiazoles via a regioselective three-component [3+2] cycloaddition and their preliminary antimicrobial evaluation , 2013, Molecular Diversity.
[54] H. Chung,et al. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells. , 2011, European journal of pharmacology.
[55] F. Da Settimo,et al. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs. , 2010, Current medicinal chemistry.
[56] Z. Incesu,et al. Synthesis of 2-substituted-N-[4-(1-methyl-4,5-diphenyl-1H-imidazole-2-yl)phenyl]acetamide derivatives and evaluation of their anticancer activity. , 2010, European journal of medicinal chemistry.
[57] H. Khavasi,et al. A novel reaction of 6-amino-uracils and isatins , 2008 .
[58] Iztok Hozo,et al. Treatment success in cancer: new cancer treatment successes identified in phase 3 randomized controlled trials conducted by the National Cancer Institute-sponsored cooperative oncology groups, 1955 to 2006. , 2008, Archives of internal medicine.
[59] P. Forterre,et al. Origin and evolution of DNA topoisomerases. , 2007, Biochimie.
[60] Alexander Kamb,et al. Why is cancer drug discovery so difficult? , 2007, Nature Reviews Drug Discovery.
[61] R. Morphy,et al. Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.
[62] J. Schellens,et al. Dual topoisomerase I/II inhibitors , 2000 .
[63] M. Lenardo,et al. Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies. , 2000, Journal of cell science.
[64] S. Kaufmann,et al. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[65] R. Hughes,et al. Screening of Hepatoprotective Plant Components using a HepG2 Cell Cytotoxicity Assay , 1997, The Journal of pharmacy and pharmacology.
[66] Y. Aoyagi,et al. Antitumor Activity of a Novel Quinoline Derivative, TAS‐103, with Inhibitory Effects on Topoisomerases I and II , 1997, Japanese journal of cancer research : Gann.
[67] J. Riou,et al. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. , 1996, European journal of cancer.
[68] C Haanen,et al. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.
[69] C. Nguyen,et al. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. , 1993, Cancer research.
[70] Y. Pommier,et al. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. , 1993, Molecular pharmacology.
[71] F. Denizot,et al. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. , 1986, Journal of immunological methods.
[72] W. Gies,et al. SUPPLEMENT , 1930 .
[73] A. A. Al-karmalawy,et al. Cordyline fruticose (L.) A. Chev. Leaves: Isolation, HPLC/MS profiling and evaluation of nephroprotective and hepatoprotective activities supported by molecular docking. , 2021, New Journal of Chemistry.
[74] V. Ravishankar,et al. Extracellular Synthesis of Selenium Nanoparticles from an Actinomycetes Streptomyces griseoruber and Evaluation of its Cytotoxicity on HT-29 Cell Line. , 2018, Pharmaceutical nanotechnology.
[75] V. Adam,et al. Selenium nanoparticles as a nutritional supplement. , 2017, Nutrition.
[76] W. Denny,et al. Dual topoisomerase I/II inhibitors in cancer therapy. , 2003, Current topics in medicinal chemistry.